SCHEMBL1273007

SCHEMBL1273007

COC(=O)C(CCSc1ccccn1)NC(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
MAPT P10636 2/20 0.44
KLK7 P49862 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC2 Q92769 2/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
TP53 P04637 1/20 0.44
LMNA P02545 1/20 0.43
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
KLK5 Q9Y337 1/20 0.43
GSTP1 P09211 1/20 0.43
GSTM2 P28161 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1273009 1.00 KMT2A (0.45) KMT2ASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL24214309 0.94 SMN1; SMN2 (0.46) KMT2ASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL1272953 0.90 PPARA (0.50) KMT2ASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL1272955 0.90 PPARA (0.50) KMT2ASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL14984808 0.85 NFKB1 (0.48) ALDH1A1KDM4EMAPTHDAC1HDAC2
SCHEMBL5144722 0.82 PPARA (0.58) SMN1; SMN2LMNACTSSCTSKPPARG
SCHEMBL16464699 0.79 HDAC6 (0.60) HDAC1NFKB1NFKB2RELACTSS
SCHEMBL16464697 0.79 HDAC6 (0.60) HDAC1NFKB1NFKB2RELACTSS
SCHEMBL22546615 0.78 CTSK (0.42) KMT2AHDAC1NFKB1NFKB2RELA
SCHEMBL22546604 0.78 CTSK (0.42) KMT2AHDAC1NFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1866277-B1 SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY INC (US) 2014-06-25 EP disclosed
US-20110281879-A1 SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2011-11-17 US disclosed
US-7893093-B2 Sulfonyl containing compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2011-02-22 US disclosed
US-20080287446-A1 Sulfonyl Containing Compounds as Cysteine Protease Inhibitors QUEST DIAGNOSTICS INVESTMENTS LLC 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281879-A1 SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS CTSS, CTSF, CTSB KMT2A 3634/4885SMN1; SMN2 3606/4885ALDH1A1 2741/4885
US-20080287446-A1 Sulfonyl Containing Compounds as Cysteine Protease Inhibitors CTSS, CTSF, CTSB KMT2A 3634/4885SMN1; SMN2 3606/4885ALDH1A1 2741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.